Expedition Therapeutics

CompanyUnited States

Expedition Therapeutics develops one asset, in phase 2 (EXPD-101 in chronic obstructive pulmonary disease). Mostly other; based in the United States.

1
Asset
Furthest stage: Phase 2; 1
Trial: 1
Signal

Pipeline

1

EXPD-101
Phase 2, Other, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease (copd) exacerbations

Full company profiles: pipeline, trials, funding and people.

In the full profile

Trials1
Signals1
Similar companies6